BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32213285)

  • 21. A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus.
    Ramadhani P; Bramantono B; Sedana MP
    Acta Med Indones; 2018 Apr; 50(2):151-158. PubMed ID: 29950535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
    Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late onset progressive multifocal leukoencephalopathy in Hodgkin lymphoma.
    Aamodt WW; Siegler JE; Viaene AN; Rubenstein MN
    J Clin Neurosci; 2017 Sep; 43():132-134. PubMed ID: 28526178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia.
    Harel A; Horng S; Gustafson T; Ramineni A; Farber RS; Fabian M
    J Neurovirol; 2018 Oct; 24(5):652-655. PubMed ID: 29987583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unusual Case of Progressive Multifocal Leukoencephalopathy in a Patient With Sjögren Syndrome.
    Onwubiko IN; Taneja K; Gupta N; Mukherjee A
    Am J Forensic Med Pathol; 2021 Jun; 42(2):186-190. PubMed ID: 33464755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature.
    Pelosini M; Focosi D; Rita F; Galimberti S; Caracciolo F; Benedetti E; Papineschi F; Petrini M
    Ann Hematol; 2008 May; 87(5):405-12. PubMed ID: 18064459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
    Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
    [No Abstract]   [Full Text] [Related]  

  • 29. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
    Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: A case report and literature review.
    Al-Tawfiq JA; Banda RW; Daabil RA; Dawamneh MF
    J Infect Public Health; 2015; 8(5):493-7. PubMed ID: 25666327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
    Verma A; Mbughuni M; Mariash E; Mesa H
    J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
    [No Abstract]   [Full Text] [Related]  

  • 32. Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab.
    Guduru M; Bendi VS; Bebawy MS; Bande D; Matta A
    Cureus; 2020 Oct; 12(10):e10888. PubMed ID: 33178540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
    Lee HJ; Schmelz JL; Cramer F; Romaguera JE; Badillo M; Wang M
    Br J Haematol; 2020 Mar; 188(6):e94-e98. PubMed ID: 32057090
    [No Abstract]   [Full Text] [Related]  

  • 35. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
    Bernard S; Goldwirt L; Amorim S; Brice P; Brière J; de Kerviler E; Mourah S; Sauvageon H; Thieblemont C
    Blood; 2015 Oct; 126(14):1695-8. PubMed ID: 26239089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
    Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
    BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive multifocal leukoencephalopathy in myelodysplastic syndrome involving pure red cell aplasia.
    Chihara D; Takeoka T; Shirase T; Kishimoto W; Arimoto-Miyamoto K; Tsuji M; Ohno T
    Intern Med; 2010; 49(21):2347-52. PubMed ID: 21048373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imbruvica
    Murthy V; Weaving S; Paneesha S
    Br J Nurs; 2017 May; 26(10):S20-S25. PubMed ID: 28541116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.